Acoramidis Has a Beneficial Effect Compared With Placebo on Change From Baseline in NAC ATTR Stage at Month 30 in Patients With ATTR-CM: Results From the ATTRibute-CM Study

IF 2.7 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Nuclear Cardiology Pub Date : 2025-08-01 DOI:10.1016/j.nuclcard.2025.102351

Julian Gillmore MD, PhD , Martha Grogan MD , Timothy Sutton MD , Matthias Dupont MD , Nowell Fine MD , Kunal Bhatt MD , Diego Delgado MD , Chris Chen PhD , Jean-Francois Tamby MD , Suresh Siddhanti PhD , Jonathan C. Fox MD, PhD , Marianna Fontana MD, PhD

引用次数: 0

查看原文本刊更多论文

与安慰剂相比，Acoramidis在atr - cm患者第30个月NAC ATTR阶段基线变化方面具有有益作用：来自属性- cm研究的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nuclear Cardiology 医学-核医学

CiteScore

5.30

自引率

20.80%

发文量

249

审稿时长

4-8 weeks

期刊介绍： Journal of Nuclear Cardiology is the only journal in the world devoted to this dynamic and growing subspecialty. Physicians and technologists value the Journal not only for its peer-reviewed articles, but also for its timely discussions about the current and future role of nuclear cardiology. Original articles address all aspects of nuclear cardiology, including interpretation, diagnosis, imaging equipment, and use of radiopharmaceuticals. As the official publication of the American Society of Nuclear Cardiology, the Journal also brings readers the latest information emerging from the Society''s task forces and publishes guidelines and position papers as they are adopted.